Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Synthelis Raises EUR 610,000

Published: Wednesday, January 22, 2014
Last Updated: Tuesday, January 21, 2014
Bookmark and Share
This initial funding enables the commercial roll-out of Synthelis’ membrane protein production using acellular technology.

Synthelis has announced that it has secured initial backing of EUR 610,000 from a group of French investors comprising Rhone-Alpes Creation, Alpes Developpement Durable Investissement (A2D-Invest), Sud Rhone-Alpes Capital, Viaduc and the Savoy and Grenoble Business Angels networks.

The aim of this initial round of funding is to speed up the development of toll manufacturing services for membrane proteins for use by R&D departments in the pharmaceutical and biotechnology industries. The funding also gives the company scope to consolidate and expand its functional and structural characterization services.

“This investment is an important step for Synthelis, allowing us to strengthen our team of scientists and invest in essential new equipment to optimize production and enhance our services,” explains Bruno Tillier, CEO of Synthelis. “Synthelis can now accelerate its commercial development, both in France and internationally.”

Founded in 2011 by Bruno Tillier to build on Professor Jean-Luc Lenormand's work at the TIMC-TheREx laboratory, part of the Universite Joseph Fourier in Grenoble, France, Synthelis develops and leverages an innovative patented technology for the acellular production of membrane proteins in the presence of liposomes.

The technology preserves the structure and the natural properties of these molecules, along with their ‘transportability’. This removes a major technological stumbling block in bio-production: previously, faithful reproductions of natural membrane proteins were difficult to manufacture in sufficient quantities.

Membrane proteins account for 60 per cent of current therapeutic targets. These membrane proteins (so called because they are embedded in the membrane which separates the cell's internal and external environments) play a role in ensuring that the cell - and therefore the organism as a whole - functions properly. Membrane protein abnormalities are also implicated in many diseases such as cancers, neuro-degenerative diseases and metabolic, genetic, immune and inflammatory disorders. In 2012, the market in which Synthelis currently operates - R&D services for the pharmaceutical industry - was valued at EUR 20 billion, with an annual growth rate of 13 per cent (source: Equity Research).

“We are pleased to be contributing to the development plans of what is a very promising young company. This is a classic case of a start-up founded on a technology coming out of a university laboratory needing financial support to make its mark as a leader in its field. The role of regional funds such as Rhone Alpes Creation and the Business Angels is to help innovative businesses like Synthelis,” adds Gwenael Hamon, senior business manager at Rhone Alpes Creation.

In two years, Synthelis has produced over 50 membrane proteins as part of more than 20 projects undertaken in conjunction with internationally-renowned pharmaceutical organizations. The success rate for protein expression across all the work undertaken by Synthelis to date is in excess of 90 per cent.

Once the initial commercial objectives have been achieved, new investment is planned in order to industrialize Synthelis’ acellular procedure and consolidate its leading position in this market. The funding will open up the market for contract manufacturing services, complementing and ensuring continuity with the existing contract research offering.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
A Peachy Defense System for Seeds
ETH chemists are developing a new coating method to protect seeds from being eaten by insects. In doing so, they have drawn inspiration from the humble peach and a few of its peers.
Fighting Cancer with Borrowed Immunity
A new step in cancer immunotherapy: researchers from the Netherlands Cancer Institute and University of Oslo/Oslo University Hospital show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Modified Microalgae Converts Sunlight into Valuable Medicine
A special type of microalgae can soon produce valuable chemicals such as cancer treatment drugs and much more just by harnessing energy from the sun.
Breakthrough Approach to Breast Cancer Treatment
Scripps scientists have designed a drug candidate that decreases growth of breast cancer cells.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Making Virus Sensors Cheap and Simple
Researchers at The University of Texas at Austin demonstrated the ability to detect single viruses in a solution containing murine cytomegalovirus (MCMV).
A Guide to CRISPR Gene Activation
A comparison of synthetic gene-activating Cas9 proteins can help guide research and development of therapeutic approaches.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!